Investorideas.com newswire, breaking biotechnology and pharma news

Thursday, September 10, 2020

#Coronavirus /#Biotechnology (#COVID19) #Stock News Bites-Reign Resources Corporation (OTCMARKETS: $RGNP) Approves Sigyn Therapeutics Merger- CEO of Sigyn former CEO of Aethlon Medical (NASDAQ: $AEMD)

 #Coronavirus /#Biotechnology (#COVID19) #Stock News Bites-Reign Resources Corporation (OTCMARKETS: $RGNP) Approves Sigyn Therapeutics Merger- CEO of Sigyn former CEO of Aethlon Medical (NASDAQ: $AEMD)

New Medical technology company focused on the treatment of life-threatening inflammatory conditions


Investorideas.com (www.investorideas.com) Coronavirus /Biotechnology (COVID-19) Stock News Bites - Reign Resources Corporation (“Reign”) (OTCMARKETS: RGNP) announced today that the Company has approved a share exchange agreement with Sigyn Therapeutics, Inc., a privately held medical technology company focused on the treatment of life-threatening inflammatory conditions.  As reported in a Schedule 14C Information statement filed today with the U.S. Securities and Exchange Commission (SEC) and a Form 8-K filed on August 31, 2020, Reign resources will acquire all of the outstanding capital stock of Sigyn Therapeutics in exchange for shares of Reign common stock representing approximately 75 percent of Reign’s outstanding common stock.  The Schedule 14C Information statement and Form 8-K can be accessed at www.SEC.gov.

Upon completion of the merger, Reign will be renamed Sigyn Therapeutics, Inc. and will be led by Sigyn co-founder Jim Joyce, who will serve as Chairman and CEO of the combined company. Sigyn Therapeutics will be focused on addressing a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (“The Cytokine Storm” or “CSS”) and not addressed with an approved therapy. The annual market opportunity for a therapeutic strategy to prevent or mitigate CSS has been reported to exceed $20 billion.  Additional announcements regarding the combined company’s management structure, Board of Directors and Science Advisory Board will be forthcoming.

Sigyn Therapy™ is a development-stage blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory conditions, including sepsis, which is the #1 cause of hospital deaths.  The mechanism of Sigyn Therapy allows for a broad-spectrum of inflammatory targets to be depleted from the bloodstream.  Among the targets are inflammatory cytokines, cytokine aggregates, endotoxin and CytoVesicles that transport cytokines and other inflammatory cargos.

Beyond sepsis, Cytokine Storm related therapeutic opportunities include, but are not limited to virus induced Cytokine Storm (a leading cause of COVID-19 deaths), bacteria induced Cytokine Storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy.  Sigyn Therapy may also be a candidate to stabilize or extend the life of patients waiting for the identification of a matched liver for transplantation.  In such a scenario, Sigyn Therapy™ would serve as a bridge-to-liver transplant. Cytokine Storm Syndrome can also result from trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies, cancer cachexia, acute kidney injury (AKI) and severe pneumonia.

Other Corporate Highlights

·         Sigyn’s co-founders have 50+ years of experience in the medical technology field and played instrumental roles in the development of three technologies that have been cleared by the FDA to treat COVID-19 infected individuals.

·         Jim Joyce, the Chairman and CEO of Sigyn Therapeutics, has two decades of public company CEO and Board leadership experience.  Specific to therapeutic blood purification, Mr. Joyce was the founder, Chairman and CEO of Aethlon Medical,  ( NASDAQ: AEMD) a company that he navigated from a single shareholder start-up to Nasdaq-traded Company with 8,000+ shareholders.

·         Sigyn Therapy aligns with U.S. government initiatives to support broad-spectrum treatment countermeasures that mitigate life-threatening conditions resulting from pandemic outbreaks such as COVID-19.

·         A deep pipeline of pre-clinical, clinical and regulatory milestones are planned over the next 12-18 months.

 

Read the company’s full news and disclaimer here:

https://finance.yahoo.com/news/reign-resources-corporation-announces-approval-184400089.html 

Visit Investorideas.com biotech and coronavirus stocks directory https://www.investorideas.com/BIS/stock_list.asp

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Stock Bites is a branded product of Investorideas.com Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. This stock bites news release publication is available as  a paid for service on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

Get free investor news alerts

https://www.investorideas.com/Resources/Newsletter.asp

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

 

Breaking #Medical #Tech/ #Covid19 #Stock News - Reign Resources Corporation (OTCMARKETS: $RGNP) Announces Approval of Sigyn Therapeutics Merger

 

Breaking #Medical #Tech/ #Covid19 #Stock News - Reign Resources Corporation (OTCMARKETS: $RGNP) Announces Approval of Sigyn Therapeutics Merger

 

#Medicaltechnology company focused on the treatment of life-threatening inflammatory conditions

 

Jim Joyce, the Chairman and CEO of Sigyn Therapeutics (OTCMARKETS: $RGNP) was founder, Chairman and CEO of Aethlon Medical (NASDAQ: $AEMD)

 


LOS ANGELES, CA, September 10, 2020 (Investorideas.com newswire) Breaking Medical Tech/ Covid- 19 stock news - Reign Resources Corporation (“Reign”) (OTCMARKETS: RGNP) announced today that the Company has approved a share exchange agreement with Sigyn Therapeutics, Inc., a privately held medical technology company focused on the treatment of life-threatening inflammatory conditions.  As reported in a Schedule 14C Information statement filed today with the U.S. Securities and Exchange Commission (SEC) and a Form 8-K filed on August 31, 2020, Reign resources will acquire all of the outstanding capital stock of Sigyn Therapeutics in exchange for shares of Reign common stock representing approximately 75 percent of Reign’s outstanding common stock.  The Schedule 14C Information statement and Form 8-K can be accessed at www.SEC.gov.

 

Read this news, featuring RGNP in full at https://www.investorideas.com/news/2020/biotech/09101RGNP-Sigyn-Therapeutics-Merger.asp

 

Upon completion of the merger, Reign will be renamed Sigyn Therapeutics, Inc. and will be led by Sigyn co-founder Jim Joyce, who will serve as Chairman and CEO of the combined company. Sigyn Therapeutics will be focused on addressing a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (“The Cytokine Storm” or “CSS”) and not addressed with an approved therapy. The annual market opportunity for a therapeutic strategy to prevent or mitigate CSS has been reported to exceed $20 billion.  Additional announcements regarding the combined company’s management structure, Board of Directors and Science Advisory Board will be forthcoming.

 

Sigyn Therapy™ is a development-stage blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory conditions, including sepsis, which is the #1 cause of hospital deaths.  The mechanism of Sigyn Therapy allows for a broad-spectrum of inflammatory targets to be depleted from the bloodstream.  Among the targets are inflammatory cytokines, cytokine aggregates, endotoxin and CytoVesicles that transport cytokines and other inflammatory cargos.

 

Beyond sepsis, Cytokine Storm related therapeutic opportunities include, but are not limited to virus induced Cytokine Storm (a leading cause of COVID-19 deaths), bacteria induced Cytokine Storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy.  Sigyn Therapy may also be a candidate to stabilize or extend the life of patients waiting for the identification of a matched liver for transplantation.  In such a scenario, Sigyn Therapy™ would serve as a bridge-to-liver transplant. Cytokine Storm Syndrome can also result from trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies, cancer cachexia, acute kidney injury (AKI) and severe pneumonia.

 

Other Corporate Highlights

·        Sigyn’s co-founders have 50+ years of experience in the medical technology field and played instrumental roles in the development of three technologies that have been cleared by the FDA to treat COVID-19 infected individuals.

 

·        Jim Joyce, the Chairman and CEO of Sigyn Therapeutics, has two decades of public company CEO and Board leadership experience.  Specific to therapeutic blood purification, Mr. Joyce was the founder, Chairman and CEO of Aethlon Medical,  ( NASDAQ: AEMD) a company that he navigated from a single shareholder start-up to Nasdaq-traded Company with 8,000+ shareholders.

 

·        Sigyn Therapy aligns with U.S. government initiatives to support broad-spectrum treatment countermeasures that mitigate life-threatening conditions resulting from pandemic outbreaks such as COVID-19.

 

·        A deep pipeline of pre-clinical, clinical and regulatory milestones are planned over the next 12-18 months.

 

About Sigyn Therapeutics

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a patent pending blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined.  Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

 

About Reign Resources Corporation

Reign Resources Corp. is a Los Angeles-based, gold exploration company with a specific focus on the Bendigo & Ballarat regions in Victoria, Australia.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Reign Resources Corporation. (“Reign”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Reign’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Reign’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Reign makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Reign’s business and the price of the common stock of Reign, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Reign’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to uplist to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Reign’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Reign related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in “Risk Factors” and elsewhere in Reign’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Reign’s views as of the date of this press release. Reign anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Reign’s views as of any date subsequent to the date of this press release.

 

Contact Reign Resources Corporation

Joseph Segelman

CEO

(213) 457 3772

info@reignsc.com

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

 

Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news release featuring (OTCMARKETS: RGNP) is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please Read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 



BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory 

Get News Alerts on Biotech Stocks 

 

Buy a biotech guest post on Investorideas.com

 

 

Friday, August 28, 2020

Investor Ideas Adds New #Stocks - #IPOs in Biotech (NYSE: $OSH), (NASDAQ: $AFIB) Tech (NASDAQ: $IBEX) (NASDAQ: $BIGC)

  

Investor Ideas Adds New #Stocks - #IPOs in Biotech (NYSE: $OSH), (NASDAQ: $AFIB) Tech (NASDAQ: $IBEX) (NASDAQ: $BIGC)

 

Plus New Stock in Homebuilder/Real Estate (NYSE: $RKT)

 


 

Point Roberts WA, Delta BC, August 28, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its free global stock directories; biotech, tech and homebuilder stocks.

 

Read this in full at https://www.investorideas.com/news/2020/main/08281Stocks.asp

 

The newest biotech/life sciences companies are involved in primary care centers, arrhythmia management, gene therapy and immunology for cancer treatment.

 

The latest tech companies are focused on cloud SaaS, e-commerce and digital media.

 

The newest homebuilder/real estate company is the well-established motrgage and ending firm, Rocket Companies, Inc. (NYSE:RKT).

 

New stocks added to Biotech stocks directory

Oak Street Health, Inc. (NYSE:OSH) Founded in 2012, Oak Street Health is a fast-growing network of value-based, primary care centers for adults on Medicare. With a mission of rebuilding healthcare as it should be, the company operates an innovative healthcare model focused on quality of care over volume of services, and assumes the full financial risk of its patients. Oak Street Health currently operates more than 50 centers across Illinois, Michigan, Indiana, Pennsylvania, Ohio, Rhode Island, North Carolina, Tennessee and Texas, with plans to continue its geographic expansion, including into New York and Mississippi, in 2020.

 

Acutus Medical, Inc. (NasdaqGS:AFIB) is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

 

Freeline Therapeutics Holdings plc (NasdaqGS:FRLN) is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the U.K. and has operations in Germany and the U.S.

 

Checkmate Pharmaceuticals, Inc. (NasdaqGS:CMPI) is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate’s product candidate, CMP-001, is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies

 

New stocks added to Tech stocks directory

IBEX Limited (NasdaqGS:IBEX) helps the world’s preeminent brands more effectively engage their customers with services ranging from customer support, technical support, inbound/outbound sales, business intelligence and analytics, digital demand generation, and CX surveys and feedback analytics.

 

BigCommerce Holdings, Inc. (NasdaqGS:BIGC) is a leading software-as-a-service (SaaS) ecommerce platform that empowers merchants of all sizes to build, innovate, and grow their businesses online. As a leading open SaaS solution, BigCommerce provides merchants sophisticated enterprise-grade functionality, customization, and performance with simplicity and ease-of-use. Tens of thousands of B2B and B2C companies across 120 countries and numerous industries use BigCommerce to create beautiful, engaging online stores, including Ben & Jerry’s, Molton Brown, S.C. Johnson, Skullcandy, Sony, Vodafone and Woolrich. Headquartered in Austin, BigCommerce has offices in San Francisco, Sydney, and London.

 

Duck Creek Technologies, Inc. (NasdaqGS:DCT) is a leading provider of core system solutions to the P&C and General insurance industry. By accessing Duck Creek OnDemand, the company’s enterprise Software-as-a-Service solution, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Duck Creek’s functionally-rich solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand.

 

New stocks added to Homebuilder stocks directory

Rocket Companies, Inc. (NYSE:RKT) is a Detroit-based holding company consisting of personal finance and consumer service brands including Rocket Mortgage, Rocket Homes, Rocket Loans, Rocket Auto, Rock Central, Amrock, Core Digital Media, Rock Connections, Lendesk and Edison Financial. Since 1985, Rocket Companies has been obsessed with helping its clients achieve the American dream of home ownership and financial freedom. Rocket Companies offers an industry-leading client experience powered by our simple, fast, and trusted digital solutions. Rocket Companies has 20,000 team members across the United States. Its flagship company, Rocket Mortgage, has been named to Fortune magazine's list of "100 Best Companies to Work For" for 17 consecutive years.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 



 

 

 

 

 

 

 

 

 

Friday, August 21, 2020

Investor Ideas Adds New Cleantech (OTC: $MKTY), Vegan (CSE: $VEGA.C) & Cannabis #Stocks (CSE: $TBI.C) to Directories

  

Investor Ideas Adds New Cleantech (OTC: $MKTY), Vegan (CSE: $VEGA.C) & Cannabis #Stocks (CSE: $TBI.C) to Directories

 

 


Point Roberts WA, Delta BC, August 21, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its global stock directories, including Cleantech, vegan, cannabis, mining and biotech.

 

Read this in full at https://www.investorideas.com/news/2020/main/08211Stocks.asp

 

The newest Cleantech stocks also crossed into the crypto sector, while the newest vegan stock is listed on both the Health, wellness and sustainability and food & beverage stock directories.

 

The latest cannabis company, Thoughtful Brands Inc (CSE:TBI) - Formerly Mota Ventures,  is an established eCommerce technology company with a strong focus on the CBD market, as well as the burgeoning psychedelic medicine sector.

 

The newest mining companies are listed on Canadian exchanges (CSE & TSX Venture) with operations in Canada, the United States and Suriname, respectively.

 

The latest biotech company is a microbiome therapeutics platform company.

 

New Stocks added to Cleantech stocks directory

Mechanical Technology, Incorporated (OTC Pink: MKTY) is engaged in the design, manufacture, and sale of test and measurement instruments and systems through its subsidiary MTI Instruments, Inc. and is developing renewable-energy powered cryptocurrency mining operations through its newest subsidiary EcoChain, Inc. 

 

New Stocks added to Vegan and plant-based stocks  

Vegaste Technologies Corp. (CSE:VEGA) As the digital face of the plant-based community, Vegaste's PlantX platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company will offer customers across North America more than 3,000 plant-based products by the end of August. In addition to offering meal and indoor plant deliveries, Vegaste currently has plans underway to expand its product lines to include cosmetics, vitamins, clothing, and its own water brand — but the business is not limited to an e-commerce platform. Vegaste uses its digital platform to build a community of like-minded consumers and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. Vegaste eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier, and happier life. The Company's lynchpin www.PlantX.com is the digital face of everything plant-based and fueled by the power of education and accessibility. For those who don't have the time to cook their own healthy plant-based meals, Vegaste offers a wide array of pre-made meals curated by Executive Chefs and nutritionists. For those looking to learn how to cook their own plant-based meals, Vegaste offers regularly updated weekly recipes. Unlike other plant-based e-commerce companies, Vegaste has a large selection of indoor plants for sale, providing not only visual appeal for your home, but unique health benefits. The site educates consumers on the benefits of a plant-based diet with a specialized blog, connects like-minded individuals with its forum, and provides resources for the best plant-based restaurants, pop-up retailers and products across Canada and the USA.

 

New stocks added to Cannabis stocks directory

Thoughtful Brands Inc (CSE:TBI) .- Formerly Mota Ventures,  is an established eCommerce technology company that researches, develops, markets and sells natural health products in North America and Europe. The Company has a strong focus on the CBD market, as well as the burgeoning psychedelic medicine sector. Through its direct-to-consumer digital platform, the Company offers multiple well-established hemp-CBD brands, including Nature’s Exclusive, Sativida and Franchise. The Company also owns and operates a 110,000 square foot manufacturing facility in Radebeul, Germany, where its highly skilled team is currently conducting clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction. The Company anticipates future opportunities to create proprietary psilocybin products as legislation related to psychedelics evolves. The Company continues to pursue the acquisition of additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its powerful eCommerce technology platform.

 

New Stocks added to Mining stocks directory

Ridgeline Minerals Corp. (TSX: RDG.V) is a discovery focused gold explorer with a proven management team and a 116 km² exploration portfolio across three projects in the highly prospective Carlin and Battle Mountain - Eureka Trends in Nevada, USA.

 

Sassy Resources Corporation (CSE:SASY) is an exploration stage resource company currently engaged in the identification, acquisition and exploration of precious metal and base metal resources in Canada.  Its current focus is on the Foremore Property located in the Eskay Camp region of Northwestern British Columbia, within the Liard Mining Division.

 

Class 1 Nickel and Technologies Limited (CSE: NICO) is a mineral exploration company focused on acquiring, exploring and developing quality mineral properties in Canada.

 

79North Inc. (CSE: JQ) formerly 12 Exploration Inc. is led by a team with extensive mineral exploration expertise and a track record of discoveries and exits in South America and globally.  79North holds an indirect interest in mineral concessions in northern Suriname (formerly Dutch Guiana), and aims to become the premier junior exploration company in this underexplored district of the prolific Guiana Shield. 79North's growing portfolio of high-quality targets which have not undergone modern exploration or drilling have a long history of artisanal mining and are strategically located within close proximity to modern gold mines operated by major mining companies.

 

New stocks added to Biotech stocks directory

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411